PHYOX3: nedosiran long-term safety and efficacy in patients with primary hyperoxaluria type 1
Lieske, John C Ariceta, Gema Groothoff, Jaap W Lipkin, Graham Moochhala, Shabbir H Schalk, Gesa Sellier-Leclerc, Anne-Laure Torres, Sara Estupiñan Rawson, Verity Zhou, Jing
Lieske, John C
Ariceta, Gema
Groothoff, Jaap W
Lipkin, Graham
Moochhala, Shabbir H
Schalk, Gesa
Sellier-Leclerc, Anne-Laure
Torres, Sara Estupiñan
Rawson, Verity
Zhou, Jing
Affiliation
Mayo Clinic; Hospital Vall d'Hebron; University Autonomous Barcelona; University of Amsterdam; Amsterdam University Medical Centers; University Hospitals Birmingham NHS Foundation Trust; Royal Free London NHS Foundation Trust; Kindernierenzentrum Bonn; Hospices Civils de Lyon; Complejo Hospitalario Universitario de Canarias; Novo Nordisk A/S, Lexington; German Hyperoxaluria Center
Other Contributors
Publication date
2025-03-25
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease characterized by oxalate overproduction in the liver, leading to hyperoxaluria, calcium oxalate stones, nephrocalcinosis, progressive chronic kidney damage, kidney failure, and systemic oxalate deposition. Nedosiran, an RNA interference therapy against lactate dehydrogenase subunit A mRNA, has been approved in the USA for treating patients with PH1 who are aged ≥ 9 years and have an estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m2. PHYOX3 (NCT04042402) is an open-label extension trial evaluating the long-term safety and efficacy of once-monthly nedosiran in patients with primary hyperoxaluria (PH).
Methods: This PHYOX3 interim analysis includes 40 participants with PH1 from PHYOX1 (NCT03392896; n = 13) and PHYOX2 (NCT03847909; n = 27) trials. Efficacy was assessed using eGFR, urinary oxalate (Uox) excretion, and clinical outcomes. Safety and efficacy of nedosiran were assessed up to 42 months.
Results: At baseline, mean (SD) age was 24.9 (9.7) years (55% females; 42.5% White), mean (SD) eGFR was 80.0 (28.6) ml/min per 1.73 m2, and median number of kidney stone events (KSEs) was 3.0. The mean eGFR range throughout the study was 71.1 to 81.5 ml/min per 1.73 m2, and mean 24-hour Uox excretion declined by ˃ 60%, maintained from month 4 to month 42. Annualized stone event rate decreased from 0.40 at baseline to 0.20 (22 events/108.8 person-years). Eight participants experienced ≥ 1 serious adverse events (AEs), none associated with nedosiran. The most common nonserious treatment-related AEs were injection site reactions (6 participants; 15%). Four participants discontinued treatments (1 pregnancy and 3 withdrawals), and no deaths were reported.
Conclusion: Nedosiran was well-tolerated, reduced average Uox levels, reduced kidney stone occurrence, and maintained stable renal function for over 3 years.
Citation
Lieske JC, Ariceta G, Groothoff JW, Lipkin G, Moochhala SH, Schalk G, Sellier-Leclerc AL, Torres SE, Rawson V, Zhou J, Hoppe B. PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1. Kidney Int Rep. 2025 Mar 25;10(6):1993-2002. doi: 10.1016/j.ekir.2025.03.031.
Type
Article